Talphera

ACRX · NASDAQ

$1.07−$0.01 (−0.93%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $1.08

ACRX analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Dec 30, 2023

Bull case

AcelRx Pharmaceuticals is well-positioned to capitalize on its product portfolio, through initiatives such as the planned Phase 3 pivotal study of Niyad and a Pre-Market Application to the FDA due in 2024. Moreover, its drug component, nafamostat, already has 30 years of real world evidence backing its safety and efficacy which could show multiple advantages over current anticoagulants used in dialysis. With data from the NEPHRO CRRT study expected in mid-2024, the stock is poised to potentially gain further upside.

Bear case

AcelRx Pharmaceuticals is a specialty pharmaceutical company with two products currently in development. Despite a solid, risk-adjusted per-share value estimated to be around $4.99, my bearish outlook is attributed to uncertainty in securing FDA approval, potential failed or equivocal trial results, and unforeseeable safety issues related to their product candidates. Additionally, their ability to raise sufficient funding at reasonable terms is an ongoing risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.